Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...

Insulet (NASDAQ:PODD – Get Free Report) had its price objective boosted by analysts at Piper Sandler from $285.00 to $310.00 ...

Insulet Corp (PODD) surpasses $2 billion in revenue with strong Omnipod 5 demand, while navigating pricing headwinds and ...

Insulet (Nasdaq:PODD) shares dipped after hours today on fourth-quarter results that came in ahead of the consensus forecast.

Canaccord raised the firm’s price target on Insulet (PODD) to $324 from $304 and keeps a Buy rating on the shares. The firm said they reported ...

Reports Q4 revenue $597.5M, consensus $582.02M. “We concluded an incredible year with a very strong fourth quarter, achieving significant ...

Q4 2024 Management View CEO Jim Hollingshead highlighted the company’s achievement of $2.1 billion in revenue for 2024, marking a doubling of revenue in just three years. He emphasized the strong ...

Insulet’s Q4 revenue hit $597.5 million, up 17.2%, beating the $582.81 million consensus. Omnipod revenue climbed 16.9% to $585.7 million, with international sales up 33.5%. Get two weeks of ...

CEO Jim Hollingshead highlighted the company’s achievement of $2.1 billion in revenue for 2024, marking a doubling of revenue in just three years. He emphasized the strong demand and adoption of ...